Atezolizumab/ipilimumab/nivolumabLymphocytic colitis : 3 case reports

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2018年 / 1700卷 / 1期

关键词：

D O I：

10.1007/s40278-018-45619-1

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：47 / 47

相关论文

共 50 条

[41] Ipilimumab/nivolumab/vemurafenibUveitis: 3 case reports
Reactions Weekly, 2016, 1606 (1) : 93 - 93
[42] Ipilimumab/nivolumab/pembrolizumabGastroparesis: 3 case reports
Reactions Weekly, 2021, 1871 (1) : 216 - 216
[43] Ipilimumab/nivolumabVarious toxicities: 3 case reports
Reactions Weekly, 2017, 1643 (1) : 167 - 167
[44] Ipilimumab/nivolumabVarious toxicities: 3 case reports
Reactions Weekly, 2020, 1816 (1) : 192 - 192
[45] Ipilimumab/Nivolumab/PembrolizumabHypophysitis: 3 case reports
Reactions Weekly, 2024, 2037 (1) : 222 - 222
[46] Ipilimumab/nivolumab/pembrolizumabMyocarditis: 3 case reports
Reactions Weekly, 2022, 1909 (1) : 303 - 303
[47] Ipilimumab/nivolumab/pembrolizumabThyroiditis: 3 case reports
Reactions Weekly, 2019, 1748 (1) : 268 - 268
[48] Ipilimumab/pembrolizumabVarious toxicities: 3 case reports
Reactions Weekly, 2016, 1631 (1) : 98 - 98
[49] Ipilimumab/nivolumabOesophagitis and pneumonitis: 3 case reports
Reactions Weekly, 2021, 1866 (1) : 226 - 226
[50] Ipilimumab/nivolumabVarious toxicities: 3 case reports
Reactions Weekly, 2022, 1902 (1) : 255 - 255

← 1 2 3 4 5 →